Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%

 
• By Dean Rudge
  
business growth
Stada's Generics And Specialty Sales Grew • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business